RP
Insider
Ra Capital Management, L.P.
DirectorRa Capital Management, L.P. (Director) filed 31 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 23 priced purchase filings, the average 21-session return was +14.9% from execution and +14.0% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+14.9%
avg across 23 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+14.0%
same 23 filings, from disclosure
Filings, ttm
31
23 buys · 8 sells · 1 late
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$847.0M
shares × price, as filed
Last traded
Sep 17
Filed yesterday
Median ADV $10.0M across their filed names
Impact on $10,000 · 12M
$27,984 (+179.8%)
S&P 500 $11,787 (+17.9%) · 162.0 pts ahead
Ra Capital Management, L.P.
S&P 500
Compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $809.9M
Sells $119.0M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
24 filings
Not on file
7 filings
Sector per market data · by filing · past 12 months
Most traded names
ARTVRecent filings
ACETPURCHASE
Adicet Bio, Inc.
View filing →
$1.6M223,596 sh across 3 lots
Exec Feb 18
Filed Apr 13 · 5:20 PM ET † SGPPURCHASE SpyGlass Pharma, Inc. View filing → $59.0M
3,690,000 sh across 2 lots
Exec Feb 9
Filed Feb 11 · 5:15 PM ET CLYMPURCHASE Climb Bio, Inc. View filing → $755K
314,561 sh across 2 lots
Exec Dec 11 2025
Filed Dec 15 2025 · 7:55 PM ET SIONSALE Sionna Therapeutics, Inc. View filing → $5.0M
124,870 sh across 10 lots
Exec Nov 17 2025
Filed Nov 19 2025 · 5:30 PM ET